Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 4/20 | 0.39 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | THRB | P10828 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA4 | P22748 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.35 |
| ▸ | PIM1 | P11309 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6838124 | 0.91 | TP53 (0.38) | TP53PAX8MAPTTHRBSMN1; SMN2 | |
| SCHEMBL6844727 | 0.91 | CA1 (0.46) | TP53CA12CA1CA2CA4 | |
| SCHEMBL6842428 | 0.90 | ALDH1A1 (0.48) | TP53PAX8MAPTTHRBSMN1; SMN2 | |
| SCHEMBL6845415 | 0.88 | PAX8 (0.42) | TP53PAX8MAPTTHRBSMN1; SMN2 | |
| SCHEMBL6196320 | 0.88 | LMNA (0.46) | MAPTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL6844813 | 0.87 | ALDH1A1 (0.45) | MAPTMEN1KMT2A | |
| SCHEMBL6193976 | 0.87 | SMN1; SMN2 (0.48) | TP53PAX8MAPTTHRBSMN1; SMN2 | |
| SCHEMBL6842398 | 0.86 | MAPT (0.41) | PAX8MAPTMEN1KMT2APIM1 | |
| SCHEMBL6842986 | 0.86 | NR4A2 (0.44) | PAX8MAPTMEN1KMT2A | |
| SCHEMBL6844771 | 0.86 | RXRA (0.44) | PAX8MAPTSMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040043983-A1 | Naphthalene derivatives as matrix metalloproteinase inhibitors | LI JIE JACK (US) | 2004-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040043983-A1 | Naphthalene derivatives as matrix metalloproteinase inhibitors | MMP9, MMP8, MMP13 | TP53 3876/4885PAX8 3028/4885MAPT 1745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.